Polypeptide variants with altered effector function
The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof.
1. A method for treating lymphoma in a mammal comprising administering to the mammal a therapeutically effective amount of a variant of a parent antibody which binds CD20 and comprises an Fc region, which variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of human effector cells more effectively than the parent antibody, wherein the Fc region of the variant is not a native sequence Fc region and comprises a variant human IgG1 Fc region comprising substitutions at positions 298, 333, and 334, thereof, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.
2. A method for treating lymphoma in a mammal comprising administering to the mammal a therapeutically effective amount of an anti-CD20 antibody which comprises a variant human IgG1 Fc region, which variant comprises substitutions at positions 298, 333 and 334 of the Fc region thereof, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.